Codexis, Inc.
Codexis, Inc. (CDXS)
Overview
Codexis is a Redwood City, California-based biocatalysis company that engineers enzymes used in pharmaceutical and biologics manufacturing. Trading on Nasdaq under CDXS, the company had a market capitalization of about $151 million as of September 2026 (down roughly 32% over the prior year), with trailing-twelve-month revenue of $77.7 million, up a strong 35.9% year over year. Second-quarter 2026 revenue reached $14.9 million with improving gross margins and a narrowed net loss; the company raised $25 million in new financing during the period and says its cash reserves should sustain operations through the end of 2028 as it builds out a new GMP manufacturing facility. Codexis employs 146 full-time and part-time staff, split roughly across R&D, operations/quality, and administrative functions, with in-house manufacturing in Redwood City supplemented by contract manufacturers in Austria, Italy, and the UK.
What They Do & How They Make Money
Codexis makes money by engineering and selling high-performance enzymes — biological catalysts — that pharmaceutical and biologics manufacturers use in place of traditional chemical processes to make drugs more efficiently, with higher yields, greater purity, and less energy and waste. Its proprietary CodeEvolver platform uses directed evolution to rapidly optimize enzymes for specific manufacturing steps, and the company organizes this technology around two go-to-market platforms: ECO Synthesis, which supplies enzymatic tools and processes for large-scale manufacturing of RNA interference (RNAi) therapeutics — a fast-growing modality where Codexis says its approach improves purity, yield, and manufacturing efficiency versus traditional phosphoramidite chemical synthesis — and Pharma Biocatalysis, which develops optimized enzymes that improve the efficiency of small-molecule drug manufacturing for pharmaceutical customers. Revenue comes from a mix of enzyme product sales, technology licensing, and research collaboration payments; major customers and partners include GSK, Merck, Novartis, Pfizer, and Nestlé Health Science, and Codexis says its enzymes are used in the manufacturing of 18 approved commercial drugs and 15 Phase 2/3 clinical candidates today, giving it a growing installed base of validated, regulatory-approved manufacturing processes.
Competitors
In RNA synthesis, Codexis names Agilent Technologies (traditional phosphoramidite chemistry), EnPlusOne Biosciences, and a CPI-led UK consortium as competitors. In enzyme engineering more broadly, it competes with Ginkgo Bioworks, BRAIN AG, and Enzymicals AG, and in general industrial enzymes it faces larger players like Novozymes, DSM-Firmenich, and Lonza.
Competitive Position
Codexis' strongest asset is regulatory and process lock-in: once a pharmaceutical customer validates a Codexis enzyme as part of an FDA-approved (or approval-track) manufacturing process, switching to a different catalyst or method requires costly re-validation and regulatory re-filing, creating real switching costs and a growing annuity-like revenue stream as its enzymes embed into 18 already-approved drugs and 15 late-stage clinical candidates. Its CodeEvolver directed-evolution platform is a genuine technical differentiator built over two decades, and the ECO Synthesis platform positions Codexis early in the fast-growing RNAi therapeutics manufacturing market against mostly traditional chemical-synthesis competitors rather than direct enzyme-engineering peers. That said, the business carries real concentration risk — one customer represented about 51% of total revenue in 2025 — and Codexis remains sub-scale and cash-constrained relative to giants like Novozymes and Lonza that could out-invest it in enzyme R&D. The combination of embedded, regulatorily-validated products and differentiated technology gives Codexis a moderate moat that is nonetheless still vulnerable to customer concentration and larger, better-capitalized competitors.